IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma ...Middle East

SHANGHAI, NANJING, China, and SAN JOSE , Calif., June 2, 2022 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, and Innovent Biologics, Inc....

Read More Details
Finally We wish PressBee provided you with enough information of ( IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma )

Also on site :

• Country 'MVP' Refunds Entire Audience Mid-Concert and Fans 'Cannot Believe He Did That'
• With Property Seized and Federal Funding Uncertain, Montana Asbestos Clinic Fights for Its Life
• Trump fija nuevo plazo de negociación de dos semanas y desencadena esfuerzo urgente por reanudar las conversaciones con Irán